Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00001159 · ClinicalTrials.gov registry record

Natural History of Thyroid Function Disorders

A clinical trial of Graves Disease and Hypothyroidism, sponsored by National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK).

Recruiting
Registry status
2,500
Enrollment target
1
Study location

NCT00001159: Recruiting study of Graves Disease and Hypothyroidism, sponsored by National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK).

NCT00001159 is a study of Graves Disease and Hypothyroidism that is actively recruiting participants, run by National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). The registered enrollment target is 2,500 participants, above the 83-participant average among 11 other Graves Disease trials with a reported enrollment target (2912% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00001159, a study of Graves Disease and Hypothyroidism, is actively recruiting participants, sponsored by National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK).

RECRUITING
Registry status
2,500 participants
Enrollment target
1
Study location

Study Summary

Participants in this study will be patients diagnosed with or suspected to have a thyroid function disorder. These conditions may include: hypothyroidism, hyperthyroidism, thyroid hormone resistance, Graves' Dermopathy, and thyroid-stimulating hormone (TSH) secreting pituitary adenomas. The main purpose of this study is to further understand the natural history, clinical presentation, and genetics of thyroid function disorders. Many of the tests performed are in the context of standard medical care that is offered to all patients with thyroid function disorders. In addition, blood and tissue samples may be taken for research and genetic studies....

Primary Outcome

Participants undergo routine history and physical examination, standard endocrine blood and urine tests, a standard TRH test, thyroid nuclear medicine scans, thyroidal radioiodine (RAI) or technetium (99mTc) uptake measurements, as well as X-ray, computed tomography (CT) or magnetic resonance imaging (MRI) studies or other standard diagnostic procedures, as clinically indicated.

Conditions Studied

Graves Disease Hypothyroidism Hyperthyroidism

Study Locations (1)

Maryland

  • National Institutes of Health Clinical Center - Bethesda

Trial Details

FieldValue
Enrollment Target 2,500 participants
Start Date 1977-02-01
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

490 total trials

What NCT00001159 shows while recruiting

NCT00001159 is an observational study that tracks outcomes without assigning an intervention. Its 2,500 participants enrollment target places it among the larger protocols in the corpus, above the 83-participant average among 11 other Graves Disease trials with a reported enrollment target (2912% higher).

The record links to 3 conditions, with Graves Disease appearing as the primary indexed condition, and to 0 interventions.

NCT00001159 reports a single indexed study location in Maryland.

Frequently Asked Questions

What is clinical trial NCT00001159 about?

NCT00001159 is a clinical study titled "Natural History of Thyroid Function Disorders". Participants in this study will be patients diagnosed with or suspected to have a thyroid function disorder. These conditions may include: hypothyroidism, hyperthyroidism, thyroid hormone resistance, Graves' Dermopathy, and thyroid-stimulating hormone (TSH) secreting pituitary adenomas. The main pu...

What is the current status of trial NCT00001159?

This trial is currently recruiting. The enrollment target is 2,500 participants. The study started on 1977-02-01.

What conditions does trial NCT00001159 study?

This clinical trial studies the following conditions: Graves Disease, Hypothyroidism, Hyperthyroidism.

Who is sponsoring clinical trial NCT00001159?

This trial is sponsored by National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), which has 490 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00001159 being conducted?

This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Graves Disease

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT00001159's enrollment target sits among peer trials

2,500 1st of 11 higher than 11 of 11 other Graves Disease trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Graves Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00001160 · 2,500 participants

    Studies on Tumors of the Thyroid

  • NCT01904188 · 2,500 participants

    Clinical Microbial Species & Antibiotic Resistance ID in ED Patients Presenting With Infection - is Rapid ID Possible & Accurate?

  • NCT02257229 · 2,500 participants

    Prospective Evaluation of Treatment for Clubfoot

  • NCT02530658 · 2,500 participants

    Next Generation Sequencing of Normal Tissues Prospectively in Pediatric Oncology Patients

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

More recruiting context for NCT00001159

Source: ClinicalTrials.gov NCT00001159, the US trial registry maintained by the National Library of Medicine. NCT00001159 (large enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.